Evidence map›Paper›PMID 40305365›Full record

ArticleBiomolecules2025

Diagnostic Utility of Bronchoalveolar Lavage Flow Cytometric Leukocyte Profiling in Interstitial Lung Disease and Infection.

Erika M Novoa-Bolivar, José A Ros, Sonia Pérez-Fernández, José A Campillo, Ruth López-Hernández, Rosana González-López, Inmaculada Ruiz-Lorente, Almudena Otálora-Alcaraz, Cristina Ortuño-Hernández, Lourdes Gimeno and 5 more

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Erika M Novoa-BolivarImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0001-9534-8779
José A RosPneumology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Sonia Pérez-FernándezDepartment of Statistics and Operations Research and Mathematics Didactics, University of Oviedo, 33007 Asturias, Spain.
José A CampilloImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Ruth López-HernándezImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Rosana González-LópezImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Inmaculada Ruiz-LorenteImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0009-0009-2433-8755
Almudena Otálora-AlcarazImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0002-4813-8119
Cristina Ortuño-HernándezImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Lourdes GimenoImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0002-3402-5842
Diana Ceballos-FranciscoImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0001-5205-5757
Manuel MuroImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0001-9987-0994
Elena Solana-MartínezPneumology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.
Pablo Martínez-CamblorDepartment of Biomedical Data Science, Geisel School of Medicine at Dartmouth, 7 Lebanon Street, Suite 309, Hinman Box 7261, Hanover, NH 03755, USA.ORCID 0000-0001-7845-3905
Alfredo MinguelaImmunology Service, Virgen de la Arrixaca University Clinical Hospital (HCUVA), Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120 Murcia, Spain.ORCID 0000-0003-2472-5893

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung diseases (ILD) represent a diverse group of disorders that primarily affect the pulmonary interstitium and, less commonly, involve the alveolar and vascular epithelium. Overlapping clinical, radiological and histopathological features make proper classification difficult, requiring multiple complementary methodologies, including flow cytometry of bronchoalveolar lavages (BAL). This retrospective study analyzed BAL flow cytometry data from 1074 real-life patients, quantifying alveolar macrophages, CD4/CD8 lymphocytes, neutrophils, eosinophils, and CD1a+ Langerhans cells, with the aim of evaluating its diagnostic utility in ILD and pulmonary infection. Clustering and logistic regression analyses identified seven distinct leukocyte profiles: lymphocytic (associated with hypersensitivity pneumonitis, cryptogenic organizing pneumonia, and lymphocytic interstitial pneumonia), sarcoidosis, macrophagic (including nonspecific interstitial pneumonia, desquamative interstitial pneumonitis, pneumoconiosis, and unclassifiable ILD), neutrophilic (including usual interstitial pneumonia, respiratory bronchiolitis ILD, and acute interstitial pneumonia), infectious diseases, eosinophilic ILD, and Langerhans cell histiocytosis. The estimated leukocyte profiles were associated with different overall survival (OS) outcomes. Neutrophilic profiles, both infectious and non-infectious, correlated with poorer OS, particularly in patients without pulmonary fibrosis. Furthermore, corticosteroids and other immunosuppressive therapies did not show significant OS differences across leukocyte profiles. Although the gold standard in BAL cytology continues to be cytopathology, these results support BAL flow cytometry as a rapid and reliable complementary tool to aid in the classification of interstitial lung diseases based on immune cell profiles, providing valuable predictive information and contributing to personalized therapeutic approaches.

Indexed as

Bronchoalveolar Lavage FluidFlow CytometryLeukocytesLung Diseases, InterstitialAdultAgedBronchoalveolar LavageFemaleHumansMaleMiddle AgedRetrospective Studiesbronchoalveolar lavageflow cytometryinterstitial lung diseaseleukocyte profilelung fibrosislung infection

Identifiers

PMID40305365
PMCPMC12025232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.